HOME >> BIOLOGY >> NEWS
The immune system may be involved in the susceptibility to childhood attention deficit hyperactivity disorder (ADHD)

Attention deficit hyperactivity disorder (ADHD) is a common neurodevelopmental disorder, characterized by inattention, hyperactivity and impulsivity. It affects 4- 10% of school age children, exacting a significant clinical and public health toll. ADHD constitutes one of the main reasons for referral to neurological/psychiatric treatment in this age group, and results in exposure of many children to prolonged courses of stimulant medication such as Ritalin. Untreated, ADHD may lead to impairments in schooling and social adaptation in a critical period of development, eventuating in damage to the childs self esteem and personality development, with high rates of depression, conduct disorder, school dropouts, and substance abuse. The causes of ADHD are unknown. Current theories suggest altered brain activity of chemical transmitters such as dopamine and norepinepherine may play a role. This is based on pharmacological observations showing reduction in symptoms in response to stimulant drugs such as Ritalin which augment dopaminergic and noradrenergic activity in relevant brain areas. However, current findings evade simplistic neurochemical explanations.

Family studies suggest a major heritable contribution to ADHD, but the mode of inheritance remains obscure. To date, the search for actual genes involved focused mainly on the dopamine system, with some findings suggesting a possible involvement of dopaminergic genes in risk for ADHD.

The current study, is the first to report the possible involvement of a gene encoding a modulator of the immune system in ADHD. Recent evidence supports the involvement of immune modulators in brain processes outside the realm of their classical role in inflammatory responses. One of the major modulators, interleukin 1 (IL-1) is expressed in the adult brain, and plays a role in maintaining neural plasticity, neuroprotection, and response to non immune stressors. Recent theories suggest it may be involved in ps
'"/>

Contact: Karl Lorenzen
molecularpsychiatry@mednet.ucla.edu
310-206-6739
Molecular Psychiatry
7-Jan-2002


Page: 1 2

Related biology news :

1. Long-term effects of carbon monoxide poisoning are an autoimmune reaction
2. Probing the surface of white blood cells to enhance immune system medicine
3. Researchers uncover secrets of immune systems munitions factory
4. Regular physical activity really does boost immune system in older men
5. New model can aid in understanding immune system diseases
6. New mechanism for display of foreign proteins to immune system
7. Babies with DiGeorge syndrome saved by immune supression, thymus transplant
8. Researchers develop better understanding of immune response to viral infection
9. Patients cells from tumors, the immune system merged for customized cancer therapy
10. Triple-vaccine strategy stimulates strong HIV-specific immune response in monkeys
11. Lack of immune system protein prevents lupus-like condition in mice

Post Your Comments:
(Date:10/15/2014)... is a non-traditional biophysics textbook and it describes how ... journey of discovery into biological systems and provides an ... It is about how our genes make proteins that ... of cells in an organism. It quantifies the principles ... can be found on both large and small scales. ...
(Date:10/15/2014)... Alt will be awarded the 44th Rosenstiel Award for ... his pioneering research exploring the mechanisms of genomic instability ... cells. Alt is the second alumnus to win the ... Prize in 2003. , Alt is the Charles A. ... Harvard Medical School and an investigator at the Howard ...
(Date:10/14/2014)... N.Y. – Scientists have sequenced the house fly genome ... one might expect from an insect that thrives in ... published Oct. 14 in the journal Genome Biology ... biology and of how flies quickly adapt to resist ... Adult house flies (Musca domestica) carry and transmit more ...
Breaking Biology News(10 mins):New book about life as seen from physics 2Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2House fly genome reveals expanded immune system 2
(Date:10/22/2014)... , Oct. 22, 2014   Synthetic Biologics, ... novel pathogen-specific therapies for serious infections and diseases, announced ... issued a Notice of Allowance for a composition of ... C. difficile program, SYN-004. This is Synthetic ... in the U.S. and adds to the Company,s extensive ...
(Date:10/22/2014)... SAN DIEGO and HONG KONG ... an innovative rare disease therapeutics enterprise, announced today that ... joined the company as vice president, research. Dr. McKew ... research, including key leadership positions at the National Institutes ... to its acquisition by Wyeth). Dr. McKew will lead aTyr,s ...
(Date:10/20/2014)... 2014 Asterias Biotherapeutics, Inc. (NYSE MKT: ... a Notice of Grant Award (NGA) with the ... 1, 2014.  The NGA provides for the immediate ... of additional grant funds pursuant to the previously ... development of Asterias, product, AST-OPC1. The grant provides ...
(Date:10/20/2014)... , Oct. 20, 2014 PureTech ... company tackling big healthcare problems, announced today the ... round, with participation from Invesco Perpetual, a $120 ... used to drive PureTech,s existing pipeline forward and ... "PureTech has the scientific creativity to really go ...
Breaking Biology Technology:Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6
Cached News: